Fish oil and atrial fibrillation

Fish Oil and Atrial Fibrillation: Measuring Before the Capsule

Fish oil raises atrial fibrillation risk in a dose-related way: across seven pooled cardiovascular trials, the hazard ratio was 1.12 at 1 g daily or below and 1.49 above 1 g. Omega-3 use above 1 g daily belongs in the vascular history and in the selection rule for metabolic and vascular screening.

Patients with gut symptoms and metabolic risk increasingly arrive self-dosed on omega-3 capsules. The trial record argues for measuring the terrain before endorsing the capsule.

The fish oil atrial fibrillation association is dose-related in pooled cardiovascular trials, and it is seldom weighed when a patient with abdominal symptoms or metabolic risk starts a high-dose capsule unprompted. Playing above is Your Gut Wall Is What You Fried Last Week, drawn from Chapter 8 of The Angry Gut by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes, which argues that the intestinal epithelium is rebuilt from dietary fat every few days and that structural lipids are a food question. For a screening practice the questions are narrower: what the fat exposure actually is, what the supplement adds to risk, and which measurements change management.

Does fish oil cause atrial fibrillation, and at what dose?

Gencer and colleagues pooled seven cardiovascular outcome trials covering 81,210 patients, mean age 65, with average follow-up of 4.9 years. Incident atrial fibrillation carried a hazard ratio of 1.12 (95% CI 1.03-1.22) at doses of 1 g daily or below, 1.49 above 1 g, and 1.11 for each additional gram. An independent meta-analysis of 15 trials returned RR 1.25 (95% CI 1.10 to 1.41), alongside modest reductions in major cardiovascular events (RR 0.95) and myocardial infarction (RR 0.90), with no overall excess of bleeding. The inflammatory bowel disease trials used 2 to 4 g daily, inside the higher band.

The supplement list therefore belongs in the vascular history. Rhythm assessment itself is electrocardiographic and sits outside a Measura protocol; what measurement adds is the metabolic and vascular context in which that rhythm risk is being accepted.

Does fish oil help Crohn’s disease or ulcerative colitis?

Enthusiasm traces to a 1996 trial of enteric-coated fish oil in Crohn’s disease, in which 11 of 39 treated patients relapsed against 27 of 39 controls. EPIC-1 and EPIC-2 then randomized 738 patients at 98 centers to 4 g daily as monotherapy. One-year relapse was 31.6% versus 35.7% in the first trial and 47.8% versus 48.8% in the second. Cochrane pooling of six trials gave RR 0.77; restricted to the two trials at low risk of bias, the estimate became 0.88 (95% CI 0.74 to 1.05). The ulcerative colitis review holds three trials and 138 patients, RR 1.02, an interval too wide to interpret. Omega-3 raised diarrhea (RR 1.36) and upper gastrointestinal symptoms (RR 1.65).

Design limits what those nulls can say. The trials enrolled a single disease and excluded the patient who presents with insulin resistance, hypertension, disordered sleep and a long medication list. For that patient the practice relies on mechanism and states the tier plainly: a food-based recommendation about membrane composition, not a trial-tier claim about a capsule.

Exposure misclassification in the fat literature

Much of the reassurance about dietary polyunsaturated fat, and much of the alarm, rests on circulating biomarkers that index an intact fatty acid, usually sampled once. That design cannot distinguish fresh oil from oil degraded by storage, heat and repeated use, which is how a large share of commercial fried fat reaches patients. The practice does not describe seed oils as toxic. It treats unmeasured oxidative degradation as a classification error in the exposure variable, one that biases toward the null for the degraded fraction.

Dairy fat carries the mirror-image problem. Plasma pentadecanoic acid tracked lower incident type 2 diabetes across 16 prospective cohorts (HR 0.80, 95% CI 0.73-0.87), yet it is the standard biomarker of dairy intake and cannot identify the food source. Assays add a second layer: resolvin D1 measures near 30 pg/ml by mass spectrometry and above 2,000 pg/ml by commercial ELISA, a gap attributed to cross-reactivity. Interpret any lipid-derived marker by its method before its magnitude.

Who to measure

A selection rule keyed to exposure rather than to gastrointestinal symptoms alone:

• Omega-3 supplementation above 1 g daily, particularly when self-initiated for gut or joint complaints.
• Chronic abdominal symptoms with metabolic features such as central adiposity, dysglycemia or elevated triglycerides.
• A dietary history dominated by fried or commercially prepared food.
• Hypertension or established vascular disease, where rhythm and vascular risk compound.
• Normal body weight with metabolic abnormalities, a phenotype BMI conceals.

Measura [Cardiometabolic and Autonomic Health Analysis] offers three measurements that fit this patient. Laboratory panels define glycemic and insulin status and the triglyceride and HDL pattern. Arterial stiffness and endothelial function assesses large-artery rigidity and the capacity of the endothelium to dilate. Bioimpedance body composition separates lean and fat compartments. Measura does not quantify tissue fatty acid composition, does not diagnose inflammatory bowel disease, and returns findings to the ordering physician.

What a finding changes

An abnormal vascular or metabolic result does not settle whether a given patient should take fish oil. It moves the decision from a population estimate to the individual: whether a high-dose capsule is supported by an indication a trial has actually tested, whether the dietary fat pattern warrants structured change, and whether separate rhythm evaluation is indicated. It also establishes a baseline. An epithelium that turns over in days responds to sustained dietary change, and the patient described in Chapter 8 improved over about five months with no way to credit any single change. Remeasurement documents whether the terrain moved.

Dr. Padda is candid that he once held the opposite view. As a strict vegetarian he cooked in the oils the guidelines endorsed and counseled patients accordingly, and the correction came from pathology rather than from a trial. The same discipline applies to the capsule: if the indication has not been tested, measure before endorsing it.

Workflow and documentation

A standing order keyed to omega-3 doses above 1 g on the medication list makes the screen reproducible. The medication review in an annual wellness visit is a natural trigger point, and results belong in structured fields covered by getting results into the record. The patient-facing account is the patient article on seed oils and testing, the full study appraisal is on the Chapter 8 book companion page, and the vascular follow-on, endothelial nitric oxide and the erectile sentinel, is in erectile dysfunction as a cardiovascular risk marker.

Frequently asked questions

Does fish oil raise atrial fibrillation risk at low doses?

In the pooled cardiovascular outcome trials, the hazard ratio was 1.12 even at 1 g daily or less, rising to 1.49 above 1 g and 1.11 per additional gram. Mean age was 65. The independent 15-trial meta-analysis found RR 1.25 while also reporting fewer major cardiovascular events and no overall rise in bleeding. The risk is dose-related rather than threshold-bound. Clinical rationale.

Is fish oil supported for maintenance of remission in Crohn’s disease?

Not by the larger trials. EPIC-1 and EPIC-2 enrolled 738 patients and found no meaningful difference in one-year relapse, and the Cochrane estimate lost significance when limited to low-risk-of-bias trials. Those trials excluded multimorbid patients and forbade concurrent therapy, which limits generalization but does not rescue the capsule. Therapeutic decisions remain with the treating gastroenterologist. Specialty applications.

Can a circulating fatty acid level stand in for dietary fat exposure?

Only partly. Circulating biomarkers index the intact fatty acid, usually from a single sample, and cannot register oil degraded before ingestion. Dairy biomarkers cannot identify food source. Treat such values as one input to a dietary history rather than as the exposure itself, and interpret any lipid mediator result by assay method first. Interpreting the report.

Which patients with gut symptoms warrant vascular and metabolic testing?

Prioritize those combining chronic abdominal symptoms with central adiposity, dysglycemia, elevated triglycerides, hypertension or high-dose omega-3 use. A normal body weight does not exclude the metabolic phenotype. Laboratory panels, arterial stiffness and endothelial function, and body composition describe the shared terrain without substituting for the gastrointestinal workup. Selection criteria.

How should the assessment be documented?

Record the trigger, the supplement dose and indication, the measurements obtained and the resulting decision in structured fields. That turns an unexamined supplement into a documented reassessment with a baseline for comparison, and it supports cardiovascular and diabetes-related quality documentation where the practice reports them. Quality measures that cardiometabolic testing supports.

Who should be careful with high-dose fish oil?

Anyone taking more than 1 g of omega-3 a day, especially when they started it on their own for gut or joint complaints. The concern grows with high blood pressure or established vascular disease, where rhythm and vascular risk compound, and with metabolic warning signs such as belly fat, high blood sugar or high triglycerides. These are the patients to measure first: laboratory panels, arterial stiffness and endothelial function, and body composition.

Why isn’t fish oil recommended for everyone?

Because the benefit in the trials is small and the tradeoffs are real. In a 15-trial analysis, fish oil trimmed major cardiovascular events only slightly (RR 0.95) while atrial fibrillation rose (RR 1.25). In Crohn’s disease, the larger trials found no meaningful drop in relapse, and the capsules raised diarrhea and upper stomach symptoms. When the reason for taking it has not been tested, measure before endorsing the capsule.

References

• Gencer, B., Djousse, L., Al-Ramady, O. T., Cook, N. R., Manson, J. E., & Albert, C. M. (2021). Effect of long-term marine ω-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: A systematic review and meta-analysis. Circulation, 144(25), 1981–1990. https://doi.org/10.1161/CIRCULATIONAHA.121.055654
• Yan, J., Liu, M., Yang, D., Zhang, Y., & An, F. (2024). Efficacy and safety of omega-3 fatty acids in the prevention of cardiovascular disease: A systematic review and meta-analysis. Cardiovascular Drugs and Therapy, 38(4), 799-817. https://doi.org/10.1007/s10557-022-07379-z
• Belluzzi, A., Brignola, C., Campieri, M., Pera, A., Boschi, S., & Miglioli, M. (1996). Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. The New England Journal of Medicine, 334(24), 1557–1560. https://doi.org/10.1056/NEJM199606133342401
• Feagan, B. G., Sandborn, W. J., Mittmann, U., Bar-Meir, S., D’Haens, G., Bradette, M., Cohen, A., Dallaire, C., Ponich, T. P., McDonald, J. W. D., Hébuterne, X., Paré, P., Klvana, P., Niv, Y., Ardizzone, S., Alexeeva, O., Rostom, A., Kiudelis, G., Spleiss, J., … Greenberg, G. R. (2008). Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. JAMA, 299(14), 1690–1697. https://doi.org/10.1001/jama.299.14.1690
• Lev-Tzion, R., Griffiths, A. M., Leder, O., & Turner, D. (2014). Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn’s disease. Cochrane Database of Systematic Reviews, 2014(2), CD006320. https://doi.org/10.1002/14651858.CD006320.pub4
• Turner, D., Steinhart, A. H., & Griffiths, A. M. (2007). Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews, CD006443. https://doi.org/10.1002/14651858.CD006443.pub2
• Imamura, F., Fretts, A., Marklund, M., Ardisson Korat, A. V., Yang, W.-S., Lankinen, M., Qureshi, W., Helmer, C., Chen, T.-A., Wong, K., Bassett, J. K., Murphy, R., Tintle, N., Yu, C. I., Brouwer, I. A., Chien, K.-L., Frazier-Wood, A. C., Del Gobbo, L. C., Djoussé, L., … Mozaffarian, D. (2018). Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies. PLoS Medicine, 15(10), e1002670. https://doi.org/10.1371/journal.pmed.1002670
• Schebb, N. H., Kühn, H., Kahnt, A. S., Rund, K. M., O’Donnell, V. B., Flamand, N., Peters-Golden, M., Jakobsson, P.-J., Weylandt, K. H., Rohwer, N., Murphy, R. C., Geisslinger, G., FitzGerald, G. A., Hanson, J., Dahlgren, C., Alnouri, M. W., Offermanns, S., & Steinhilber, D. (2022). Formation, signaling and occurrence of specialized pro-resolving lipid mediators — what is the evidence so far? Frontiers in Pharmacology, 13, 838782. https://doi.org/10.3389/fphar.2022.838782

Related reading

• Orthostatic Intolerance in Hypermobility: A Primary Care Screen
• Erectile Dysfunction Cardiovascular Risk: A Sentinel in Primary Care
• Laboratory Panels

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.